<DOC>
	<DOCNO>NCT02494258</DOCNO>
	<brief_summary>Rollover study support solid tumor hematological disorder indication Celgene sponsor CC-486 protocol eligible participation study .</brief_summary>
	<brief_title>A Study Evaluate Long-term Safety Subjects With Solid Tumors Hematological Disorders .</brief_title>
	<detailed_description>The open-label , multicenter , multinational rollover study intend evaluate safety CC-486 , provide continued treatment CC-486 subject receive single agent CC-486 time transition rollover study tolerate protocol prescribe regimen Celgene-sponsored trial , opinion Investigator may derive clinical benefit continue treatment CC-486 . Subjects ' survival also follow required parent CC-486 study protocol . If approve Celgene , subject ongoing future Celgene sponsor CC-486 study solid tumor hematological disorder include protocol .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Previously participate , receive oral azacitidine , continue fulfill eligibility criteria one parent oral azacitidine clinical trial . The Investigator believe subject tolerate treatment oral azacitidine monotherapy continue oral azacitidine treatment benefit subject . 2 . Understand voluntarily sign informed consent document prior study related assessment procedure conduct . 3 . Willing able adhere study visit schedule protocol requirement . 4 . Females childbearing potential ( FCBP ) may participate , provide meet following condition : 1 . Have two negative pregnancy test verify Investigator prior start study therapy . She must agree ongoing pregnancy test course study , end study treatment . This apply even subject practice true abstinence heterosexual contact . 2 . Either commit true abstinence heterosexual contact ( must review monthly basis source document ) agree use , able comply , effective contraception without interruption , 28 day prior start investigational product , study therapy ( include dose interruption ) , 3 month , longer required local regulation , discontinuation study therapy . 5 . Male subject must : 1 . Practice true abstinence ( must review monthly basis ) agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption least 3 month , longer required local regulation , follow Investigational Product ( IP ) discontinuation , even undergone successful vasectomy . Subjects must satisfy follow criterion participate Survival Followup phase : 1 . In order enrol survival followup Followup Phase rollover study , subject must parent oral azacitidine study monitor survival require sign informed consent followup phase . 2 . Understand voluntarily sign informed consent document study . 3 . Willing able adhere study visit schedule protocol requirement . The presence follow exclude subject receive investigational product study : 1 . Concomitant use drug prohibit . 2 . Prior chemotherapy ( include injectable azacitidine ) radiotherapy investigational agent last dose oral azacitidine administer part parent oral azacitidine study . 3 . Subjects meet one criterion discontinuation stipulate parent oral azacitidine study . 4 . Subjects receive oral azacitidine combination another compound parent oral azacitidine study ( Subjects form multiarm parent oral azacitidine study allow enroll rollover study , subject receive singleagent oral azacitidine time transition rollover study ) . 5 . A subject 's transition rollover study â‰¥ 45 day End Study visit parent oral azacitidine study 6 . Pregnant lactating female . There exclusion criterion prevent entry remain followup phase study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>CC-486</keyword>
	<keyword>Oral Azacitidine</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>hematological disorder</keyword>
	<keyword>rollover study</keyword>
</DOC>